Abstract
Since the outbreak of coronavirus disease (COVID-19) in Wuhan, China, triggered by
severe acute respiratory coronavirus 2 (SARS-CoV-2) in late November 2019, spreading to more
than 200 countries of the world, the ensuing pandemic to an enormous loss of lives, mainly the
older population with comorbidities, like diabetes, cardiovascular disease, chronic obstructive
pulmonary disease, obesity, and hypertension. Amongst these immune-debilitating diseases,
SARS-CoV-2 infection is the most common in patients with diabetes due to the absence of a normal
active immune system to fight the COVID-19. Recovery of patients having a history of diabetes
from COVID-19 encounters several complications, and their management becomes cumbersome.
For control of coronavirus, antiviral medications, glucose-lowering agents, and steroids have
been carefully evaluated. In the present review, we discuss the crosstalk between SARS-CoV-2 infection
and patients with a history of diabetes. We mainly emphasize the molecular factors that are
involved in diabetic individuals recently infected by SARS-CoV-2 and developed COVID-19 disease.
Lastly, we examine the medications available for the long-term management of diabetic patients
with SARS-CoV-2 infection.